Katja Seipel

Bern, BE 3010, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 68 publications

Clinical Impact of a Common PDCD1 Germline Variant in DLBCL Patients Treated with CAR-T Cell Therapy.

Clinical Impact of a Common PDCD1 Germline Variant in DLBCL Patients Treated with CAR-T Cell Therapy.

Journal: International journal of molecular sciences

Published: July 09, 2026

Clinical Impact of a Germline CD19 Variant on Treatment Outcome After CAR-T Cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma.

Clinical Impact of a Germline CD19 Variant on Treatment Outcome After CAR-T Cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma.

Journal: Cancers

Published: June 03, 2026

Low-Frequency PPM1D Gene Mutations Affect Treatment Response to BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma.

Low-Frequency PPM1D Gene Mutations Affect Treatment Response to BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma.

Journal: Cancers

Published: May 19, 2026

Influence of PPM1D Mutations on Response and Survival Outcomes Following Bispecific Antibody Therapy in Relapsed and Refractory Multiple Myeloma Patients.

Influence of PPM1D Mutations on Response and Survival Outcomes Following Bispecific Antibody Therapy in Relapsed and Refractory Multiple Myeloma Patients.

Journal: Biomedicines

Published: May 18, 2026

Elevated Allele Frequency of a Common Germline LAG3 Variant Associated with Anemia, Thrombocytopenia and Peripheral Blast Percentage in Acute Myeloid Leukemia.

Elevated Allele Frequency of a Common Germline LAG3 Variant Associated with Anemia, Thrombocytopenia and Peripheral Blast Percentage in Acute Myeloid Leukemia.

Journal: Cancers

Published: April 23, 2026

Clinical Impact of the CTLA4 rs231775 Polymorphism in Acute Myeloid Leukemia Treated with Autologous Stem Cell Transplantation.

Clinical Impact of the CTLA4 rs231775 Polymorphism in Acute Myeloid Leukemia Treated with Autologous Stem Cell Transplantation.

Journal: Cancers

Published: April 23, 2026

Prophylactic Anakinra to Prevent Neurotoxicity After CAR T-Cell Therapy in Aggressive B-Cell Lymphomas: A Single-Center Real-World Experience.

Prophylactic Anakinra to Prevent Neurotoxicity After CAR T-Cell Therapy in Aggressive B-Cell Lymphomas: A Single-Center Real-World Experience.

Journal: Cancers

Published: April 17, 2026

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy: Results of a Real-World Study.

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy: Results of a Real-World Study.

Journal: Cancers

Published: April 05, 2026

Analysis of Clinical Impact of CD33 rs12459419 Single-Nucleotide Polymorphism in AML Treated with Intensive Chemotherapy Without Gemtuzumab Ozogamicin.

Analysis of Clinical Impact of CD33 rs12459419 Single-Nucleotide Polymorphism in AML Treated with Intensive Chemotherapy Without Gemtuzumab Ozogamicin.

Journal: International journal of molecular sciences

Published: April 05, 2026

Disease Stage-Dependent Clinical Impact of CTLA4 Polymorphism in Multiple Myeloma Treated with Autologous Stem Cell Transplantation.

Disease Stage-Dependent Clinical Impact of CTLA4 Polymorphism in Multiple Myeloma Treated with Autologous Stem Cell Transplantation.

Journal: Cancers

Published: February 12, 2026

Clinical Impact of a LAG3 Single-Nucleotide Polymorphism in Relapsed, Refractory DLBCL Patients Treated with Glofitamab.

Clinical Impact of a LAG3 Single-Nucleotide Polymorphism in Relapsed, Refractory DLBCL Patients Treated with Glofitamab.

Journal: Cancers

Published: February 06, 2026

AL Amyloidosis Patients Continue to Benefit from HDCT/ASCT Consolidation in the Daratumumab Era.

AL Amyloidosis Patients Continue to Benefit from HDCT/ASCT Consolidation in the Daratumumab Era.

Journal: Journal of clinical medicine

Published: December 24, 2025

Showing 1-12 of 68

Last Updated: 09/26/2026